S
0.183
0.01 (4.80%)
| Previous Close | 0.175 |
| Open | 0.170 |
| Volume | 2,975,826 |
| Avg. Volume (3M) | 4,732,457 |
| Market Cap | 2,014,520 |
| Price / Book | 0.610 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.77 |
| Total Debt/Equity (MRQ) | 33.61% |
| Current Ratio (MRQ) | 2.78 |
| Operating Cash Flow (TTM) | -8.62 M |
| Levered Free Cash Flow (TTM) | -4.73 M |
| Return on Assets (TTM) | -115.04% |
| Return on Equity (TTM) | -346.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Shuttle Pharmaceuticals Holding | - | - |
AIStockmoo Score
-0.9
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -1.0 |
| Average | -0.88 |
|
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 14.18% |
| % Held by Institutions | 2.30% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jun 2025 | Announcement | Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative |
| 12 Jun 2025 | Announcement | Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time |
| 04 Jun 2025 | Announcement | Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors |
| 15 May 2025 | Announcement | Shuttle Pharma Provides Corporate Update |
| 08 May 2025 | Announcement | Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial |
| 21 Apr 2025 | Announcement | Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 |
| 10 Apr 2025 | Announcement | Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |